drugset / Trial / NCT06542614
Treatment of Moderate to Severe Plaque Psoriasis
Phase 2
Completed
209 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses
Timeline
- Start
- 2024-08-27
- Primary completion
- 2025-11-03
- Completion
- 2025-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH3906 | Small molecule | — | Oral |